SCHEMBL195374

SCHEMBL195374

CCCC[Sn](CCCC)(CCCC)c1ccc(-n2cnc(C)c2)c(OC)n1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.43
CYP2C9 P11712 4/20 0.43
CYP2C19 P33261 4/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP19A1 P11511 1/20 0.43
PSEN1 P49768 19/20 0.42
PSEN2 P49810 19/20 0.42
APH1B Q8WW43 19/20 0.42
NCSTN Q92542 19/20 0.42
APH1A Q96BI3 19/20 0.42
PSENEN Q9NZ42 19/20 0.42
KCNH2 Q12809 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236636 0.83 PSEN1 (0.32) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3793452 0.81 CYP1A2 (0.40) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL20021828 0.77 PSEN1 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL20021981 0.77 PSEN1 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL194561 0.76 PSEN1 (0.49) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6127800 0.76 PSEN1 (0.49) CYP3A4CYP2C9CYP2C19CYP2D6PSEN1
SCHEMBL12668349 0.76 PSEN1 (0.46) CYP3A4CYP2C9CYP2C19CYP1A2PSEN1
SCHEMBL15104419 0.75 PSEN1 (0.47) CYP3A4CYP2C9CYP2C19CYP1A2PSEN1
SCHEMBL154721 0.72 PSEN1 (0.47) CYP3A4CYP2C9CYP2C19CYP2D6PSEN1
SCHEMBL909536 0.72 PSEN1 (0.51) CYP2C19CYP2D6PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
EP-2615090-A1 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors Eisai R&D Management Co., Ltd. (JP) 2013-07-17 EP disclosed
EP-2401276-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MAN CO LTD (JP) 2013-06-05 EP disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
EP-2401276-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2012-01-04 EP disclosed
WO-2010098487-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed
WO-2010098488-A1 ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors BACE1, APP, PSEN1 CYP3A4 1585/4885CYP2C9 2129/4885CYP2C19 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.